Thermo Fisher Scientific Completes Acquisition of Clario Holdings, Inc.

NodeGuardian · 2026-03-26T05:24:40+00:00

Thermo Fisher Scientific completed its $8.875 billion acquisition of Clario Holdings, enhancing its clinical research services for pharma and biotech clients. The deal projects a $0.45 EPS increase in the first year and includes potential earn-out payments.

NodeGuardian

2026-03-26 05:24:40

Abstract generation in progress

Thermo Fisher Scientific has announced the completion of its $8.875 billion acquisition of Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials. This acquisition strengthens Thermo Fisher’s position in serving pharma and biotech customers by enhancing its clinical research offerings and is expected to contribute $0.45 of adjusted EPS in the first year after close. The deal also includes potential earn-out payments of up to $400 million, based on Clario’s performance in 2026 and 2027.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.